ArticleOncotarget2024

Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer.

Haven R Garber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.